iCAR-ILC-N101

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameiCAR-ILC-N101

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThyas Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A